Company: IMRX
Filing Date: 2025-09-03
Form Type: S-3
Source: 0001104659-25-086561
Chunk: 11

Company: Immuneering Corp
Filing Date: 2025-09-03
Form: S-3
Chunk 11
---
 of the combined voting power of our outstanding share capital, and subject to certain additional restrictions as more particularly described in our Certificate of Incorporation. Shares of Class B common stock, once converted to shares of Class A common stock, may not be converted back into shares of Class B common stock.

#### Preferred Stock
Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. The issuance of our preferred stock could adversely affect the voting power of holders of Class A common stock and the likelihood that such holders, including the holders of Class B common stock,

<div align='center'>8</div>

TABLE OF CONTENTS

will receive payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Warrants Pre-Funded Warrants On August 21, 2025, we entered into a securities purchase agreement with certain purchasers named therein, pursuant to which we agreed to sell securities to such purchasers in a private placement. In the private placement, the purchasers had the option to purchase either shares of our Class A common stock or, in lieu thereof, pre-funded warrants, or the Pre-Funded Warrants, to purchase shares of our Class A common stock, each with an exercise price of $0.001 per share. Accordingly, we issued Pre-Funded Warrants to purchase 1,077,764 shares of our Class A common stock upon the closing of the private placement. As of September 2, 2025, Pre-Funded Warrants to purchase an aggregate of 1,077,764 shares of our Class A common stock were outstanding. The Pre-Funded Warrants are exercisable until such Warrant is exercised in full. The exercise price and number of shares of Class A common stock issuable upon exercise of the Pre-Funded Warrants may be adjusted in certain circumstances, including in the event of a stock dividend, a forward or reverse split of our shares of Class A common stock, and certain other events. However, the